hiv-1

HIV-1 Rev (34-50) (HIV-1 rev Protein (34-50)) is a 17-amino acid peptide with anti-HIV-1 activity, derived from the Rev-responsive element-binding domains of Rev in HIV-1.

HIV-1 Nef-IN-1 is an inhibitor of the HIV-1 Nef protein, effectively competing for Nef-SH3Hck interactions (Kd: 6.7 μM).

HIV-1 inhibitor-6 (3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(5-nitro-1,2-benzisothiazol-3-yl)-4-oxo-) is a potent HIV-1 pre-mRNA selective splicing inhibitor that blocks HIV replication.

HIV-1 inhibitor-3 is an HIV infection inhibitor.

HIV-1 integrase inhibitor 7 is a potent inhibitor of HIV-1 integrase (IC50: 33.3 nM).

Hiv-1 integrase inhibitor is an effective anti-HIV drug.

HIV-1 integrase inhibitor 3 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

HIV-1 integrase inhibitor 4 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.

HIV-1 Inhibitor 18A (HIV-1 Inhibitor-18A) specifically inhibits the entry of multiple HIV-1 isolates.

(Cys47)-HIV-1 tat Protein (47-57) possesses membrane translocation functionality and can serve as a surface derivatization agent for magnetic pharmaceuticals, enhancing their uptake into specific target cells.

HIV-1 TAT (48-60) is a cell-penetrating peptide derived from the human immunodeficient virus (HIV)-1 Tat protein residue 48-60. This is one of the cell-penetrating peptides generated from the human immunodeficient virus -1 Tat protein residue 48-60.

HIV-1 inhibitor-54 is a potent inhibitor of WT HIV-1 (strain IIIB) in MT-4 cells, demonstrating anti-HIV activity with an EC50 of 32 nM. [HIV-1 inhibitor-54 can be used to study viral infections.]

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

HIV-1inhibitor-74 (compound 10c) is a potent inhibitor of HIV-1, displaying an EC50 of 0.0047 µM against HIV-1IIIB. It exhibits cytotoxic properties and effectively inhibits the activity of WTHIV-1RT with an IC50 of 0.134 µM. Additionally, HIV-1inhibitor-74 demonstrates broad-spectrum anti-HIV-1 activity.

HIV-1inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor with an EC50 range of 0.0039-0.338 μM. Its target is the reverse transcriptase, exhibiting an IC50 value of 0.055 μM. Additionally, HIV-1inhibitor-75 demonstrates good metabolic stability in vitro, presenting moderate clearance rates and an extended half-life in human plasma and liver microsomes.

HIV-1protease-IN-14 (compound 5ae) is an effective inhibitor of HIV-1protease, exhibiting Ki values of 0.28 nM and 56.9 nM against WTHIV-1PR and R41THIV-1PR, respectively. This compound also demonstrates low cytotoxicity.

HIV-1inhibitor-76 (compound 9t-2) is an inhibitor of the HIV-1 non-nucleoside reverse transcriptase. It is utilized in research aimed at combating HIV.

HIV-1inhibitor-77 (compound 13) is an HIV-1 inhibitor capable of neutralizing three different viruses: HIV-1CH58TF, HIV-1JRFL, and HIV-1AD8. The IC50 values for these viruses are 0.14 μM, 8.28 μM, and 2.92 μM, respectively.

HIV-1inhibitor-79 (Compound 3k) is an HIV inhibitor that demonstrates significant inhibitory activity against HIV-1 and its common mutants, with IC50 values of 1.9 nM for HIV-1, K103, 8.7 nM for L100I, and 11 nM for E138K. It exhibits low cytotoxicity and a high selectivity index (CC50 = 21.95 μM, SI = 11478). Additionally, HIV-1inhibitor-79 shows antiviral activity against HIV-2, with an EC50 value of 6.14 μM, and effectively inhibits HIV-1 reverse transcriptase with an IC50 of 25 nM.

HIV-1inhibitor-78 (compound 15f) is a potent and broad-spectrum non-nucleoside reverse transcriptase inhibitor, with an EC50 value of 3 nM against wild-type HIV-1. It is useful for research on HIV infections.

HIV-1inhibitor-80 (compound M44) is an HIV-1 inhibitor with an EC50 of 5-148 nM. It demonstrates excellent metabolic stability and low cytotoxicity in human plasma and liver microsomes.

HIV-1inhibitor-81 (Compound 14g) is an HIV-1 protease inhibitor with a Ki of 1.6 nM. This compound exhibits antiviral activity against HIV-1, with an EC50 value of 250 nM.

HIV-1inhibitor-82 (Compound L14) is a small molecule inhibitor of HIV-1 entry with oral bioavailability, exhibiting an IC50 value of 0.39 μM. It holds potential for research in combating HIV-1 infection.

HIV-1protease-IN-13 (compound 18d) is a potent inhibitor of HIV-1 protease (HIV-1protease) with an IC50 value of 0.54 nM. Additionally, HIV-1protease-IN-13 demonstrates effective activity against both HIV-1DRVRS (DRV resistant mutation) and HIV-1NL4_3 variants (wild-type).